324 filings
Page 4 of 17
8-K
n6vm1cxru0oc0yz5
10 May 21
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint
8:00am
8-K
peabzgty43rr
19 Apr 21
Departure of Directors or Certain Officers
4:30pm
8-K
av9dctd4clt4
30 Mar 21
PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results
7:00am
8-K
pgqryi rn80pheyp1fs
9 Mar 21
Regulation FD Disclosure
7:00am
8-K
ed03q
10 Feb 21
PolarityTE Provides Corporate Update
8:00am
8-K
nvbtj0
3 Feb 21
PolarityTE Receives Allowance for Additional U.S. Patent
5:25pm
8-K
vh51epr5
27 Jan 21
Other Events
8:00am
8-K
dmfnjw9hb3t5x0
26 Jan 21
Entry into a Material Definitive Agreement
4:30pm
8-K
79mzs guydjade9mjm
22 Jan 21
PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million
8:55am
8-K
mc62dhgubpceg
21 Jan 21
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial
8:00am
8-K
xm5 lbxqamo9eig
14 Jan 21
PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:15pm
8-K
bu22l4tb 79
12 Jan 21
PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:15am
8-K
5yg85l 7zu4k7nkhz03
11 Jan 21
PolarityTE Announces Formation of Strategic Review Committee
8:15am
8-K
4k6 9a4hpqv
23 Dec 20
Entry into a Material Definitive Agreement
4:05pm
8-K
orte9ezv
22 Dec 20
PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
8:15am
8-K
rhe9 06ch
11 Dec 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
psgm 0ll6dba
30 Nov 20
PolarityTE Receives Allowance for First U.S. Patent
8:00am
8-K
7azyawgr
23 Nov 20
Submission of Matters to a Vote of Security Holders
8:05am
8-K
g9otu9pc7z7
9 Nov 20
PolarityTE Reports Third Quarter 2020 Results
7:00am
8-K
zxxgmqeavxr4utnf
2 Nov 20
PolarityTE Announces Successful Completion of Initial
8:01am